Anti-DR4 antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution

Not available outside of the UK & Ireland.

Application

Anti-DR4 antibody produced in rabbit has been used in western blotting.

Biochem/physiol Actions

Soluble tumor necrosis factor-related apoptosis-inducing ligand-receptor 1 (sTRAIL-R1) interacts with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and stimulates cell-death signaling pathway. Mutation of the sTRAIL-R1 gene is associated with the pathogenesis of non-Hodgkin′s lymphoma (NHL). In addition, variation of TRAIL-R1 also increases the risk of susceptibility to prostate cancer (PCa) in North Indian population.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Features and Benefits

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

General description

Soluble tumor necrosis factor-related apoptosis-inducing ligand-receptor 1 (sTRAIL-R1), also known as DR4, is encoded by the gene mapped to human chromosome 8p21-22. It belongs to the TNFR superfamily of transmembrane proteins. TRAIL-R1 contains a cytoplasmic "death domain," which can activate the cell’;s apoptotic machinery. TRAIL receptor-1/DR4 is activated by binding to either membrane anchored or soluble TRAIL/Apo2L.

Immunogen

DR4 antibody was raised against a peptide corresponding to amino acids near the carboxy terminus of human DR4 protein.

Linkage

The action of this antibody can be blocked using blocking peptide SBP3500428.

Physical form

Supplied in PBS with 0.02% sodium azide.